ERUDITE Study for Schizophrenia (H-51727)
If you’re having trouble with memory or focus caused by schizophrenia, the ERUDITE Study may be of interest to you. This study is researching an investigational medication that is being assessed for the treatment of cognitive impairment associated with schizophrenia.
Who Can Participate?
Eligible participants must:
- Be between 18 and 50 years of age (inclusive)
- Have a confirmed diagnosis of schizophrenia
- Already be receiving antipsychotic therapy for schizophrenia
- Not have a lifetime diagnosis of schizoaffective disorder, bipolar disorder, or obsessive-compulsive disorder
- Not have had an occurrence of panic disorder or depression within the past 6 months
- Not be pregnant or breastfeeding
The total length of study participation is up to 46 weeks, which includes 10 on-site study visits and five telemedicine visits.
Participants will receive study-related medical care and investigational study medication at no cost and may be eligible for compensation for time and travel.